CR20160177A - PHARMACEUTICAL DOSAGE FORMS INCLUDING 1- [6- (MORFOLIN-4-IL) PIRIMIDIN-4-IL] -4- (1H-1,2,3-TRIAZOL-1-IL) 1H-PIRAZOL-5-OLATO SODIUM - Google Patents
PHARMACEUTICAL DOSAGE FORMS INCLUDING 1- [6- (MORFOLIN-4-IL) PIRIMIDIN-4-IL] -4- (1H-1,2,3-TRIAZOL-1-IL) 1H-PIRAZOL-5-OLATO SODIUMInfo
- Publication number
- CR20160177A CR20160177A CR20160177A CR20160177A CR20160177A CR 20160177 A CR20160177 A CR 20160177A CR 20160177 A CR20160177 A CR 20160177A CR 20160177 A CR20160177 A CR 20160177A CR 20160177 A CR20160177 A CR 20160177A
- Authority
- CR
- Costa Rica
- Prior art keywords
- triazol
- dosage forms
- pharmaceutical dosage
- sodium
- morfolin
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 2
- 229910052708 sodium Inorganic materials 0.000 title abstract 2
- 239000011734 sodium Substances 0.000 title abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 125000001607 1,2,3-triazol-1-yl group Chemical group [*]N1N=NC([H])=C1[H] 0.000 abstract 1
- XBYRMPXUBGMOJC-UHFFFAOYSA-N 1,2-dihydropyrazol-3-one Chemical compound OC=1C=CNN=1 XBYRMPXUBGMOJC-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se relaciona con formas sólidas de dosificación farmacéutica para administración oral que comprenden1-[6-(morfolin-4-il)pirimidin-4-il]-4- (1H-1,2,3-triazol-1-il)-1H-pirazol-5-olato de sodio (ingrediente activo (I)), caracterizadas porque el ingrediente activo (I) se libera, y también métodos para la preparación de las mismas, uso de las mismas como medicamentos, y también el uso de las mismas para profilaxis, profilaxis secundaria o el tratamiento de trastornos, particularmente trastornos cardiovasculares, fallo cardiaco, anemia, trastornos renales crónicos e insuficiencia renal.The present invention relates to solid pharmaceutical dosage forms for oral administration comprising 1- [6- (morpholin-4-yl) pyrimidin-4-yl] -4- (1 H-1,2,3-triazol-1-yl ) -1H-Sodium pyrazole-5-olate (active ingredient (I)), characterized in that the active ingredient (I) is released, and also methods for preparing them, using them as medicines, and also the use thereof for prophylaxis, secondary prophylaxis or the treatment of disorders, particularly cardiovascular disorders, heart failure, anemia, chronic renal disorders and renal failure.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14071855 | 2014-10-13 | ||
| PCT/EP2014/071855 WO2015055564A1 (en) | 2013-10-17 | 2014-10-13 | Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20160177A true CR20160177A (en) | 2016-06-29 |
Family
ID=56609572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20160177A CR20160177A (en) | 2014-10-13 | 2016-04-15 | PHARMACEUTICAL DOSAGE FORMS INCLUDING 1- [6- (MORFOLIN-4-IL) PIRIMIDIN-4-IL] -4- (1H-1,2,3-TRIAZOL-1-IL) 1H-PIRAZOL-5-OLATO SODIUM |
Country Status (1)
| Country | Link |
|---|---|
| CR (1) | CR20160177A (en) |
-
2016
- 2016-04-15 CR CR20160177A patent/CR20160177A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| SA518391624B1 (en) | ROR- gamma regulators | |
| PH12018500284B1 (en) | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| BR112015020118A2 (en) | 2-aminopyrimidine derivatives for the treatment of viral infections | |
| CL2020001762A1 (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative of procytentan. (divisional request 201902464) | |
| PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| BR112015011036A2 (en) | heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | |
| MX2016012574A (en) | Substituted heteroaryl compounds and methods of use. | |
| CL2015002608A1 (en) | Amino-pyrazole compound and related medicinal uses. | |
| MY201535A (en) | Therapeutic compounds | |
| MX392182B (en) | FIXED-DOSE COMBINATIONS AND FORMULATIONS COMPRISING 8-HYDROXY-2,2,14,14 TETRAMETHYLPENTADECANEDIOIC ACID (ETC1002) AND EZETIMIBE AND METHODS FOR TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE. | |
| MX377919B (en) | SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING BIOPTERIN DERIVATIVES AND USES OF SUCH COMPOSITIONS. | |
| MX2017013636A (en) | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles. | |
| MX383792B (en) | OCULAR FORMULATIONS FOR DRUG ADMINISTRATION AND PROTECTION OF THE ANTERIOR SEGMENT OF THE EYE. | |
| BR112015028890A2 (en) | Pyridone derivatives for the treatment of viral infections and other diseases | |
| EA201691231A1 (en) | PHARMACEUTICAL MEDICINE FORMS | |
| AR107935A1 (en) | USE OF COMPOUND 6- (4- (2,3-DIMETHYLPHENOXY) PIPERIDIN-1-IL) METHYL) PYRIMIDINE-2,4 (1H, 3H) -DIONA OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME TO PREPARE A MEDICINAL, COMBINATION AND COMPOSITION PHARMACEUTICAL UNDERSTANDING SUCH COMPOUND | |
| UA116499C2 (en) | (R) -PIRLINDOL AND ITS PHARMACEUTICALLY ACCEPTED SALTS FOR MEDICINAL USE | |
| MX2017013633A (en) | FIXED DOSE COMBINATION RESISTANT TO HANDLING THAT PROVIDES A QUICK RELEASE OF TWO PHARMACES FROM PARTICLES. | |
| DOP2016000078A (en) | PHARMACEUTICAL DOSAGE FORMS INCLUDING 1- [6- (MORFOLIN-4-IL) PIRIMIDIN-4-IL] -4- (1H-1,2,3-TRIAZOL-1-IL) -1H-PIRAZOL-5-OLATO OF SODIUM | |
| BR112014032264A8 (en) | Composition for the treatment or prevention of diseases related to vascular permeability, containing imatinib or a pharmaceutically acceptable salt thereof as an active ingredient | |
| CR20160177A (en) | PHARMACEUTICAL DOSAGE FORMS INCLUDING 1- [6- (MORFOLIN-4-IL) PIRIMIDIN-4-IL] -4- (1H-1,2,3-TRIAZOL-1-IL) 1H-PIRAZOL-5-OLATO SODIUM | |
| EA201891848A1 (en) | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF FIBROSIS | |
| BR112017014295A2 (en) | pharmaceutical composition. | |
| MX384394B (en) | COMPOUND FOR USE IN THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES. |